Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,115 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03263637 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT00615160 | PTK/ZK in Disseminated Malignant Melanoma | terminated | Phase 1 / Phase 2 | 9 | Michael WeichenthalOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT04252248 |
| Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage(DERANO) |
| terminated |
| Phase 1 |
| 3 |
| University Hospital HeidelbergOTHER |
| 1 |
| Oct 6, 2021 |
| clinicaltrials |
| NCT01353625 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | completed | Phase 1 | 118 | CelgeneINDUSTRY | 4 | Oct 5, 2021 | clinicaltrials |
| NCT02770378 | A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 10 | University of UlmOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT02406742 | A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(ENHANCE) | completed | Phase 1 / Phase 2 | 47 | CelgeneINDUSTRY | 5 | Sep 20, 2021 | clinicaltrials |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Molecular Partners AGINDUSTRY | 6 | Aug 25, 2021 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041639 | Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer | completed | Phase 1 / Phase 2 | 75 | Gilead SciencesINDUSTRY | 4 | Aug 19, 2021 | clinicaltrials |
| NCT00421395 | Safety Study of NHL With 90Y-hLL2 IgG | completed | Phase 1 / Phase 2 | 59 | Gilead SciencesINDUSTRY | 2 | Aug 16, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT02521870 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 241 | Dynavax Technologies CorporationINDUSTRY | 4 | Aug 3, 2021 | clinicaltrials |
| NCT02992483 | Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma | completed | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 3, 2021 | clinicaltrials |
| NCT03098550 | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | completed | Phase 1 / Phase 2 | 105 | Bristol-Myers SquibbINDUSTRY | 9 | Jul 23, 2021 | clinicaltrials |
| NCT03360734 | Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors(GATTO) | completed | Phase 1 | 50 | Glycotope GmbHINDUSTRY | 3 | Jul 12, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT01275222 | Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Jun 25, 2021 | clinicaltrials |
| NCT02718144 | Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer | completed | Phase 1 / Phase 2 | 12 | Pantarhei Oncology B.V.OTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT01760525 | A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors(CCGM097X2101) | completed | Phase 1 | 51 | Novartis PharmaceuticalsINDUSTRY | 5 | Jun 15, 2021 | clinicaltrials |
| NCT01188681 | Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 79 | Aptevo TherapeuticsINDUSTRY | 5 | Jun 10, 2021 | clinicaltrials |
| NCT01222637 | CetuGEX™: Phase 1 Study in Cancer Patients | completed | Phase 1 | 41 | Glycotope GmbHINDUSTRY | 3 | May 25, 2021 | clinicaltrials |
| NCT02143635 | Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | completed | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 8 | May 21, 2021 | clinicaltrials |
| NCT01222624 | PankoMab-GEX™: Phase 1 Dose Escalation Study | completed | Phase 1 | 74 | Glycotope GmbHINDUSTRY | 3 | May 20, 2021 | clinicaltrials |
| NCT01693562 | A Phase 1/2 Study to Evaluate MEDI4736 | completed | Phase 1 / Phase 2 | 1,022 | MedImmune LLCINDUSTRY | 9 | May 13, 2021 | clinicaltrials |
| NCT04536454 | Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside)(SenPET) | unknown | Phase 1 / Phase 2 | 32 | University Hospital TuebingenOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT01409343 | TrasGEX™: Phase 1 Study in Cancer Patients | completed | Phase 1 | 37 | Glycotope GmbHINDUSTRY | 4 | May 7, 2021 | clinicaltrials |
| NCT01976741 | Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib) | completed | Phase 1 | 168 | BayerINDUSTRY | 7 | May 6, 2021 | clinicaltrials |
| NCT01765790 | Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors | completed | Phase 1 | 68 | Baxalta now part of ShireINDUSTRY | 2 | May 5, 2021 | clinicaltrials |
| NCT02564367 | Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction(S-1 adjuvant) | completed | Phase 1 / Phase 2 | 30 | AIO-Studien-gGmbHOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT03172884 | Study of Copanlisib in Hepatic or Renal Impairment | completed | Phase 1 | 30 | BayerINDUSTRY | 2 | Apr 28, 2021 | clinicaltrials |
| NCT02481960 | Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma(IDEB-glioma) | terminated | Phase 1 / Phase 2 | 5 | Boston Scientific CorporationINDUSTRY | 2 | Apr 21, 2021 | clinicaltrials |
| NCT04712396 | A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body | completed | Phase 1 | 11 | AstraZenecaINDUSTRY | 1 | Apr 9, 2021 | clinicaltrials |
| NCT01075048 | ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 131 | Daiichi SankyoINDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT01251640 | Combination With Gemcitabine in Advanced Pancreatic Cancer(BAGPAC) | completed | Phase 1 / Phase 2 | 90 | BayerINDUSTRY | 9 | Apr 8, 2021 | clinicaltrials |
| NCT03305913 | Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy(REMETY) | completed | Phase 1 | 12 | AIO-Studien-gGmbHOTHER | 1 | Mar 26, 2021 | clinicaltrials |
| NCT02291614 | A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer | terminated | Phase 1 | 45 | AmgenINDUSTRY | 2 | Mar 16, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT00306202 | Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia | completed | Phase 1 | 63 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 26, 2021 | clinicaltrials |
| NCT02902042 | Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma(IMMU-TARGET) | completed | Phase 1 / Phase 2 | 16 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT02668393 | Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma | completed | Phase 1 | 14 | Boehringer IngelheimINDUSTRY | 2 | Jan 29, 2021 | clinicaltrials |
| NCT03227016 | Study in Patients With SCLC of Veliparib in Combination With Topotecan | unknown | Phase 1 | 30 | Central European Society for Anticancer Drug ResearchOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT02572687 | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | completed | Phase 1 | 85 | Eli Lilly and CompanyINDUSTRY | 8 | Jan 20, 2021 | clinicaltrials |
| NCT00621244 | A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | completed | Phase 1 / Phase 2 | 175 | Novartis PharmaceuticalsINDUSTRY | 3 | Jan 5, 2021 | clinicaltrials |
| NCT01268059 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 99 | MedImmune LLCINDUSTRY | 7 | Dec 23, 2020 | clinicaltrials |
| NCT00434174 | Safety of Everolimus and Pemetrexed in Lung Cancer Patients | completed | Phase 1 | 48 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 21, 2020 | clinicaltrials |
| NCT00446082 | Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease | completed | Phase 1 | 85 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 21, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials